Maria Fleseriu

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi request reprint Treatment options for Cushing disease after unsuccessful transsphenoidal surgery
    James K Liu
    Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Neurosurg Focus 23:E8. 2007
  2. doi request reprint The role of combination medical therapy in acromegaly: hope for the nonresponsive patient
    Maria Fleseriu
    Department of Medicine, Northwest Pituitary Center, Oregon Health and Science University, Portland, Oregon 97239, USA
    Curr Opin Endocrinol Diabetes Obes 20:321-9. 2013
  3. pmc New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy
    Maria Fleseriu
    Departments of Medicine and Neurological Surgery, and Northwest Pituitary Center, Oregon Health and Science University, Portland, OR 97239, USA
    J Neurooncol 114:1-11. 2013
  4. doi request reprint A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone
    Maria Fleseriu
    Oregon Health and Science University, Portland, OR 97239, USA
    Endocr Pract 19:313-26. 2013
  5. doi request reprint Medical management of persistent and recurrent cushing disease
    Maria Fleseriu
    Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Neurosurg Clin N Am 23:653-68. 2012
  6. ncbi request reprint Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome
    Maria Fleseriu
    Northwest Pituitary Center, Department of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Clin Endocrinol Metab 97:2039-49. 2012
  7. doi request reprint Normal hypothalamic-pituitary-adrenal axis by high-dose cosyntropin testing in patients with abnormal response to low-dose cosyntropin stimulation: a retrospective review
    Maria Fleseriu
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    Endocr Pract 16:64-70. 2010
  8. ncbi request reprint Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions
    Maria Fleseriu
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon, USA
    J Neurosurg 110:354-8. 2009
  9. ncbi request reprint "Relative" adrenal insufficiency in critical illness
    Maria Fleseriu
    Department of Medicine, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, BTE 472, Portland, OR 97239, USA
    Endocr Pract 15:632-40. 2009
  10. ncbi request reprint Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful
    Maria Fleseriu
    Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA
    Curr Opin Endocrinol Diabetes Obes 14:323-8. 2007

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Treatment options for Cushing disease after unsuccessful transsphenoidal surgery
    James K Liu
    Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Evanston Northwestern Healthcare, Evanston, Illinois 60201, USA
    Neurosurg Focus 23:E8. 2007
    ..The indications, current results reported in the literature, and complications of each treatment modality are discussed...
  2. doi request reprint The role of combination medical therapy in acromegaly: hope for the nonresponsive patient
    Maria Fleseriu
    Department of Medicine, Northwest Pituitary Center, Oregon Health and Science University, Portland, Oregon 97239, USA
    Curr Opin Endocrinol Diabetes Obes 20:321-9. 2013
    ..This review focuses on combination drug treatment for acromegaly patients, including novel concepts and experimental therapies, with an emphasis on the author's personal experience...
  3. pmc New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy
    Maria Fleseriu
    Departments of Medicine and Neurological Surgery, and Northwest Pituitary Center, Oregon Health and Science University, Portland, OR 97239, USA
    J Neurooncol 114:1-11. 2013
    ..Pituitary-targeted medical therapies will soon play a more prominent role in treating CD, and may potentially become first-line medical therapy when surgery fails or is contraindicated. ..
  4. doi request reprint A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone
    Maria Fleseriu
    Oregon Health and Science University, Portland, OR 97239, USA
    Endocr Pract 19:313-26. 2013
    ..Our objective is to review the pharmacology and clinical use of this novel agent and to discuss detailed guidance on the management of CS patients treated with mifepristone...
  5. doi request reprint Medical management of persistent and recurrent cushing disease
    Maria Fleseriu
    Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Neurosurg Clin N Am 23:653-68. 2012
    ..The development of new therapeutic agents has been eagerly anticipated. This article discusses the results of currently available and promising new therapeutic agents used to treat this challenging disease...
  6. ncbi request reprint Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome
    Maria Fleseriu
    Northwest Pituitary Center, Department of Medicine, Oregon Health and Science University, Portland, Oregon 97239, USA
    J Clin Endocrinol Metab 97:2039-49. 2012
    ..Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations...
  7. doi request reprint Normal hypothalamic-pituitary-adrenal axis by high-dose cosyntropin testing in patients with abnormal response to low-dose cosyntropin stimulation: a retrospective review
    Maria Fleseriu
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    Endocr Pract 16:64-70. 2010
    ....
  8. ncbi request reprint Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions
    Maria Fleseriu
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon, USA
    J Neurosurg 110:354-8. 2009
    ..If conventional medical management fails, transsphenoidal surgery (TSS) may be considered as an alternative treatment for intractable headaches...
  9. ncbi request reprint "Relative" adrenal insufficiency in critical illness
    Maria Fleseriu
    Department of Medicine, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, BTE 472, Portland, OR 97239, USA
    Endocr Pract 15:632-40. 2009
    ..To present a recommended approach to the problem of "relative" adrenal insufficiency (RAI) in the intensive care unit (ICU)...
  10. ncbi request reprint Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful
    Maria Fleseriu
    Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA
    Curr Opin Endocrinol Diabetes Obes 14:323-8. 2007
    ..It is successful in about 80% of patients in the hands of an experienced surgeon. When transsphenoidal surgery fails or is contraindicated, a second-line treatment must be chosen. The review focuses on second-line treatment options...
  11. pmc Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
    Maria Fleseriu
    Department of Neurological Surgery, Northwest Pituitary Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, BTE 472, Portland, OR 97239, USA
    Pituitary 14:184-93. 2011
    ..Furthermore, patients should routinely have their GH and IGF-1 levels closely monitored and their SRL dose increased or decreased thereafter according to individual response...
  12. doi request reprint Acromegaly: a review of current medical therapy and new drugs on the horizon
    Maria Fleseriu
    Department of Neurological Surgery, Division of Endocrinology, Diabetes, and Clinical Nutrition, and Northwest Pituitary Center, Oregon Health and Science University, Portland, Oregon 97239, USA
    Neurosurg Focus 29:E15. 2010
    ..Because a surgical cure can be difficult to achieve, all patients, even those with what seems to be a clinically and biochemically inactive disease, should undergo long-term biochemical testing and pituitary MR imaging...
  13. pmc Medical management of Cushing's disease: what is the future?
    Maria Fleseriu
    Departments of Medicine and Neurological Surgery, Northwest Pituitary Center, Oregon Health and Science University, Portland, OR, USA
    Pituitary 15:330-41. 2012
    ..Our aim is to expand awareness of current research, and the possibilities afforded by available medical treatments for this mesmerizing, but often frightful disease...
  14. ncbi request reprint Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing's disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience
    Nadia Hameed
    Department of Medicine, Oregon Health and Science University, Portland, OR, USA
    Pituitary 16:452-8. 2013
    ..7%. ACTH measurements correlate well with cortisol. However, because no single cortisol or ACTH cutoff value excludes all recurrences, patients require long-term clinical and biochemical follow-up. Further research is needed in this area...
  15. ncbi request reprint Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience
    Jessica Brzana
    OHSU Northwest Pituitary Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Road BTE 472, Portland, OR, 97239, USA
    Pituitary 16:490-8. 2013
    ..These immunoreactive markers should be assessed routinely on surgical specimens to assess subsequent SRL responsiveness and potential need for adjunctive therapy after surgery...
  16. doi request reprint Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
    Jessica A Brzana
    Department of Medicine, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR 97239, USA
    Pituitary 15:562-70. 2012
    ..Further studies with larger patient populations and longer follow-up are required to determine the long-term implications of discordant GH and IGF-1 value patterns...
  17. doi request reprint Temozolomide for corticotroph pituitary adenomas refractory to standard therapy
    Troy H Dillard
    Division of Endocrinology, Diabetes, and Clinical Nutrition, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    Pituitary 14:80-91. 2011
    ..To our knowledge, this case represents the most rapid robust CA shrinkage response reported to date. Further randomized clinical trials of TMZ in the treatment of aggressive pituitary adenomas are warranted...
  18. doi request reprint Relative adrenal insufficiency
    Donald L Loriaux
    Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA
    Curr Opin Endocrinol Diabetes Obes 16:392-400. 2009
    ..This article will review the clinical presentation, diagnosis, and treatment of acute adrenal insufficiency and explore the concept of 'relative adrenal insufficiency' in the critically ill...
  19. doi request reprint Adrenal and pancreatic presentation of subdiaphragmatic retroperitoneal bronchogenic cysts
    Raphael El Youssef
    Department of Surgery, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239 3098, USA
    Arch Surg 145:302-4. 2010
    ..We present 1 case of an adrenal lesion and 1 case of a pancreatic lesion that were revealed to be retroperitoneal bronchogenic cysts after surgical extirpation...
  20. ncbi request reprint LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study
    Xavier Bertagna
    Department of Endocrinology X B, Centre de Référence des Maladies Rares de la Surrénale, Hopital Cochin, Faculté de Médecine Paris Descartes, Universite Paris 5, Paris 75014, France Dipartimento di Medicina Clinica e Chirurgia R P, Universita Federico II di Napoli, IT 80131, Naples, Italy Department of Medicine and Neurological Surgery M F, Northwest Pituitary Center, Oregon Health and Science University, Portland, Oregon 97239 3098 Novartis Pharmaceuticals Corporation Y Z, East Hanover, New Jersey 07936 Novartis Pharmaceuticals UK Limited P R, Horsham, West Sussex, RH12 5AB, United Kingdom Novartis Institutes for BioMedical Research A T, C E W, Cambridge, Massachusetts 02139 Clinical Development M M, Oncology Business Unit, Novartis Pharma AG, CH 4002 Basel, Switzerland Department of Endocrinology, Diabetes, and Metabolism A H H, Cleveland Clinic Foundation, Cleveland, Ohio 44106 Division of Endocrinology M B, Polytechnic University of Marche, 60121 Ancona, Italy and Neuroendocrine Clinical Center B M K B, Massachusetts General Hospital, Boston, Massachusetts 02114
    J Clin Endocrinol Metab 99:1375-83. 2014
    ..As LCI699 potently inhibits 11β-hydroxylase, which catalyzes the final step of cortisol synthesis, it is a potential new treatment for Cushing's disease, the most common cause of endogenous Cushing's syndrome...
  21. ncbi request reprint Polycystic ovarian syndrome and Cushing's syndrome: a persistent diagnostic quandary
    Jessica Brzana
    Department of Medicine, Division of Endocrinology, Portland, OR, USA
    Eur J Obstet Gynecol Reprod Biol 175:145-8. 2014
    ..To determine whether clinical patterns might be useful in identifying appropriate candidates for hypercortisolism screening in women suspected of PCOS...
  22. ncbi request reprint Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study
    Chris G Yedinak
    OHSU Northwest Pituitary Center, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd BTE472, Portland, OR, USA
    Endocrine 46:585-93. 2014
    ..Further research may be useful regarding patient quality of life, patient functionality during normal daily activities, and perceived dysfunction despite biological disease control. ..
  23. ncbi request reprint Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
    Troy Dillard
    Department of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, OR, USA
    Pituitary 13:29-38. 2010
    ..We recommend mandatory long term follow-up to monitor the development of other hormonal deficits...
  24. ncbi request reprint Diabetes insipidus, panhypopituitarism, and severe mental status deterioration in a patient with chordoid glioma: case report and literature review
    Kristine Dziurzynski
    Department of Neurological Surgery, Oregon Health and Science University, Portland, Oregon 97239, USA
    Endocr Pract 15:240-5. 2009
    ..To describe a rare progressive case of chordoid glioma clinically masquerading as idiopathic diabetes insipidus (DI)...